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Abstract
Introduction Lysophosphatidic acid (LPA) is a bioactive
phospholipid with diverse effects on various cells. It interacts
with at least three G-protein-coupled transmembrane receptors,
namely LPA1, LPA2 and LPA3, whose expression in various
tumours has not been fully characterized. In the present study
we characterized the expression profile of LPA receptors in
human breast cancer tissue and assessed the possible roles of
each receptor.
Methods The relative expression levels of each receptor's
mRNA against β-actin mRNA was examined in surgically
resected invasive ductal carcinomas and normal gland tissue
using real-time RT-PCR. LPA2 expression was also examined
immunohistochemically using a rat anti-LPA2 monoclonal
antibody.
Results In 25 cases normal and cancer tissue contained LPA1
mRNA at similar levels, whereas the expression level of LPA2
mRNA was significantly increased in cancer tissue as compared
with its normal counterpart (3479.0 ± 426.6 versus 1287.3 ±
466.8; P < 0.05). LPA3 was weakly expressed in both cancer
and normal gland tissue. In 48 (57%) out of 84 cases, enhanced
expression of LPA2 protein was confirmed in carcinoma cells as
compared with normal mammary epithelium by
immunohistochemistry. Over-expression of LPA2 was detected
in 17 (45%) out of 38 premenopausal women, as compared
with 31 (67%) out of 46 postmenopausal women, and the
difference was statistically significant (P < 0.05).
Conclusion These findings suggest that upregulation of LPA2
may play a role in carcinogenesis, particularly in
postmenopausal breast cancer.
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Introduction
Lysophosphatidic acid (LPA; 1- or 2-acyl-sn-glycero-3-
phosphate), the simplest glycerophospholipid, mediates a
broad range of cellular responses including smooth muscle
cell contraction, platelet aggregation, neurite retraction/cell
rounding, regulation of cell proliferation, protection from
apoptosis, modulation of chemotaxis and transcellular
migration [1-3]. Previous reports have also demonstrated
that LPA stimulates proliferation, migration and production
of matrix metalloproteinases and angiogenic factors in ovar-
ian cancer cell lines [4-9]. Moreover, a high level of LPA has
been detected in ascitic fluid from ovarian cancer patients
[4,10,11]. These findings suggest that LPA may be a medi-
ator of tumour development and progression [12].
At least three receptors – LPA1/Edg-2, LPA2/Edg-4 and
LPA3/Edg-7 – have been identified as specific receptors
for LPA [13,14]. These LPA receptors differ with respect to
their distribution in various tissues. LPA1 is broadly
expressed in various normal tissues, whereas expression
levels of LPA2 and LPA3 are more restricted, which may
account for the various biological effects of LPA [13,14]. In
recent studies LPA1 and LPA2 were found to have redun-
dant functions in mediating multiple endogenous LPA
responses, including phospholipase C activation, calcium
mobilization, cell proliferation and stress fibre formation in
mouse embryonic fibroblast cells [15,16]. However, in the
same study the different phenotypes of knockout mice for
each receptor suggested distinct roles for LPA1 and LPA2
in vivo.
IGF = insulin-like growth factor; LPA = lysophosphatidic acid; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; RT = reverse 
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Previous studies also found that malignant transformation
resulted in aberrant expression of LPA2 or LPA3 in ovarian
or thyroid cancers, suggesting that LPA may play a role in
tumour biology and that shifts in LPA receptor expression
are related to carcinogenesis [17-20]. However, patterns
of expression of these LPA receptors in other tumours have
not been adequately examined. In the present study we
characterized the expression patterns of LPA receptors in
human breast cancer tissue (another common form of can-
cer in females) and analyzed correlations with other clinical
and pathological findings to determine the possible role
played by each LPA receptor in the development of breast
cancer.
Methods
Patients and materials
In the first part of the study, mRNA expression for each LPA
receptor was evaluated in 25 cases of invasive ductal car-
cinoma, which were surgically resected in the Department
of Surgery, University of Tokyo, from 1998 to 2003, and in
six samples of adjacent normal gland tissue. In the next part
of the study, protein expression of LPA2 was evaluated by
immunohistochemical staining in the 25 cases and an addi-
tional 59 cases of invasive ductal carcinoma, which were
resected from 1992 to 1997, also in the Department of
Surgery, University of Tokyo.
All of the resected primary tumours and regional lymph
nodes were histologically examined by haematoxylin–eosin
staining, in accordance with the International Union Against
Cancer TNM classification. Several discrete histological
parameters and lymph node metastasis were also exam-
ined. Oestrogen receptor levels were evaluated using
enzyme immunoassay of frozen tumour specimens with cut-
off levels for positivity of 5 fmol/mg protein.
Isolation of total RNA and reverse transcription
The tumour tissue resected from the primary lesion and
paired nontumour tissue (taken 10 cm away from the neo-
plasm) were immediately frozen in liquid nitrogen and kept
at -80°C until extraction of RNA. Total RNA was extracted
from each sample using the acid guanidine isothiocyanate/
phenol/chloroform extraction method. One microgram of
total RNA was reverse transcribed using a SuperScript
First-Strand Synthesis System (Invitrogen Co., Carlsbad,
CA, USA). The reverse transcription reaction was carried
out in a total volume of 20 µl, in accordance with the man-
ufacturer's instructions. The cDNA was stored at -20°C
until use.
Preparation of cDNA calibrators
We used pcDNA3 vector (Invitrogen) containing LPA1,
LPA2, or LPA3 as the standard cDNA for each LPA recep-
tor [14]. cDNA for human β-actin was prepared using
human colon cDNA as the template DNA and the following
oligonucleotides: CCATCGAATTCACCACCATGGAT-
GATGATATCGCCGCGCTC and AAGGTGCG-
GCCGCCTAGAAGCATTTGCGGTGGACGAT. The
resulting DNA fragments were digested by EcoRI/NotI and
ligated into pBlueScript (Strategene, La Jolla, CA, USA).
The DNA sequence of cDNA prepared by RT-PCR was
confirmed by DNA sequencing and used to calibrate for β-
actin.
Real-time fluorescence quantitative PCR
The primers used in the analysis of LPA1, LPA2, LPA3 and
β-actin gene expression are given in Table 1. All the primers
were designed using Primer Express software (Applied
Biosystems, Foster, CA, USA). Real-time PCR reactions
were conducted in an ABI PRISM 7000 (Perkin-Elmer/
Applied Biosystems, Foster, CA, USA) using SYBR Green
I (Perkin-Elmer) with the following profile: one step at 50°C
for 2 min, one step at 95°C for 10 min, and 40 cycles at
95°C for 30 s and 60°C for 1 min. Thermocycling was done
in a final volume of 20 µl containing 1 µl of cDNA sample.
The ABI PRISM software constructed the calibration curve
by plotting the crossing point against the logarithm of the
number of copies for each calibrator. The number of copies
in unknown samples was calculated by comparing their
crossing points with the calibration curve. To correct for dif-
ferences in both RNA quality and quantity between sam-
ples, data were normalized using the ratio of the target
cDNA concentration to that of β-actin. Both RT and PCR
reactions were performed in triplicate, and the mean values
were calculated against against β-actin.
Table 1
Lysophosphatidic acid receptor 2 (LPA2) expression evaluated by RT-PCR and immunohistochemistry
Immunohistochemistry findings Relative mRNA expression P
<3000 >3000
Low expression 10 1
High expression 3 11 <0.001Available online http://breast-cancer-research.com/content/6/6/R640
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Monoclonal antibodies against human LPA2
A peptide consisting of the carboxyl-terminal 17 amino
acids of human LPA2 (335–351) was conjugated with key-
hole limpet haemocyanin. The conjugate was injected into
the hind foot pads of WKY/Izm rats using Freund's com-
plete adjuvant. The enlarged medial iliac lymph nodes from
the rats were used for cell fusion with mouse myeloma cell
line PAI. The antibody-secreting hybridoma cells were
selected by screening with enzyme-linked immunosorbent
assay, immunofluorescence and Western blotting. Several
clones were established. In this study, monoclonal antibody
from clone 10D5 (rat IgG1) was used for immunohisto-
chemical staining.
Specificity of the monoclonal antibody against human LPA2
used in the present study (clone 10D5) was confirmed as
follows. HeLa cells were transfected with LPA1-pcDNA3,
LPA2-pcDNA3, LPA3-pcDNA3, or empty pcDNA3 vector
using lipofectamine 2000 (Invitrogen). Twenty-four hours
after transfection, the cells were rinsed with phosphate-
buffered saline (PBS) and recovered using a cell scraper.
Protein (10 µg) was separated on SDS-PAGE (12.5%
polyacrylamide) and transferred onto nitrocellulose transfer
membrane (Schleicher & Schuell, Einbeck, Germany).
Using the enhanced chemiluminescence (ECL) method,
the expression of each receptor was confirmed using anti-
LPA1, anti-LPA2, or anti-LPA3 antibodies (Fig. 1).
Immunohistochemical study of LPA2
Expression of LPA2 was examined by immunohistochemi-
cal staining using the anti-LPA2 antibody. Sections (3 µm
thick) were deparaffinized in xylene, hydrated through a
gradually diluted ethanol series, and heated in a microwave
oven for two 7-min cycles (500 W). After being rinsed in
PBS, endogenous peroxidase activity was inhibited by
incubation with 0.3% hydrogen peroxide in 100% metha-
nol for 30 min. After washing three times in PBS, nonspe-
cific reaction was blocked by incubation with PBS
containing 5% skimmed milk for 30 min at room tempera-
ture, and then the sections were incubated with normal rab-
bit serum for 30 min. The sections were incubated
overnight at 4°C in humid chambers with the primary anti-
body to LPA2 at a dilution of 1/100. As negative control,
anti-LPA1 monoclonal antibody (rat IgG1), as well as con-
trol rat IgG (Nichirei, Tokyo, Japan), was used. After wash-
ing three times with PBS, the sections were incubated with
biotinylated rabbit antirat immunoglobulin for 30 min. After
washing again with PBS, the slides were treated with per-
oxidase-conjugated streptavidin for 30 min, and developed
by immersion in 0.01% hydrogen peroxide and 0.05%
diaminobenzidine tetrahydrochloride for 3 min, followed by
light counterstaining with Mayer's haematoxylin. Immunore-
activity was assessed by two evaluators who had no knowl-
edge of the background features. When more than half of
the carcinoma cells in these fields exhibited significantly
stronger staining intensity than the corresponding epithe-
lium from normal mammary glands, these tumours were
defined as having high expression of LPA2. In other
tumours, most of the carcinoma cells exhibited only weak,
if any, immunostaining, and, if present, the staining intensity
was similar to that of normal epithelium; these tumours
were thus defined as having low expression of LPA2.
Statistical analysis
All statistical calculations were conducted using StatView-
J 5.0 statistical software (SAS Institute, Cary, NC, USA).
mRNA levels were compared using unpaired Student's t-
test, and relationships between the over-expression of
LPA2 and clinicopathological features were examined by
Fisher's exact test. P < 0.05 was considered statistically
significant.
Results
Expression of LPA receptors at the mRNA level
The relative expression level of each LPA receptor's mRNA
was quantitatively evaluated by real-time RT-PCR against
that of β-actin (Fig. 2). A significant level of LPA1 mRNA
was detected in both normal and carcinoma tissues, and
expression levels did not differ significantly between tis-
sues (1438.5 ± 425.5 versus 1675.3 ± 299.8). However,
the expression level of LPA2 in cancer tissue was signifi-
cantly greater than that in normal tissue (3479.0 ± 426.6
versus 1287.3 ± 466.8; P < 0.05). In comparison, LPA3
Figure 1
Specificity of anti-human lysophosphatidic acid receptor 2 (LPA2)  antibody Specificity of anti-human lysophosphatidic acid receptor 2 (LPA2) anti-
body. The cross-reactivity of anti-human LPA2 (clone 10D5) was exam-
ined by Western blotting. Cell lysate of HeLa cells transfected with 
human lysophosphatidic acid receptor 1 (LPA1; lane1), LPA2 (lane 2), 
LPA3 (lane 3), or empty vector (lane4) were loaded onto SDS-PAGE. 
After the proteins were transferred onto nitrocellulose membrane, the 
LPA2 protein was detected using antihuman LPA2 antibody (clone 
10D5) in an enhanced chemiluminescence (ECL) system. 10D5 did not 
exhibit cross-reactivity to LPA1 or LPA3.Breast Cancer Research    Vol 6 No 6    Kitayama et al.
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was weakly expressed in both normal and cancer tissue,
although one cancer contained a relatively high level of
LPA3 transcript. When the ratio of LPA2 to LPA1 was cal-
culated, cancer tissue exhibited a threefold higher ratio
than did normal gland tissue (3.69 ± 0.96 versus 1.12 ±
0.43; P = 0.0016).
Expression of LPA2 receptor in the 
immunohistochemical study
The expression of LPA2 in the same tumours was also eval-
uated at the protein level by immunohistochemical staining
(Fig. 3). In 15 out of 25 (60%) carcinomas, enhanced stain-
ing for LPA2 was clearly detected in comparison with nor-
mal tissue. In these carcinoma cells, LPA2 was detectable
in the cytoplasm and in the cell membrane, but not in the
nucleus. Some of the normal epithelium in the same speci-
mens, as well as interstitial cells, also stained slightly, but
the intensity was significantly weaker than that in carcinoma
cells in the 15 tumours. Thus, these cases were catego-
rized as tumours with high LPA2 expression. In the other 10
tumours, carcinoma cells exhibited apparently the same
staining intensity as normal epithelium and were catego-
rized as having low expression of LPA2.
When the immunoreactivity was compared with the relative
ratio of LPA2 mRNA against β-actin, 11 out of the 12
tumours (92%) with ratios greater than 3000 had high
expression of LPA2, whereas 10 out of 13 tumours with a
ratio below 3000 had low expression (Table 1). Thus, the
results of the immunohistochemical study exhibited signifi-
cant correlation with the results of quantitative mRNA study
in breast cancer tissue (P < 0.001).
Relationship between LPA2 expression and clinical and 
pathological factors
Because LPA2 expression showed a strong correlation
between mRNA and protein levels in 25 cases, we per-
formed immunostaining of LPA2 in an additional 59 cases.
The relations between LPA2 expression and clinical or
Figure 2
Relative expression level of lysophosphatidic acid receptors' mRNA against β-actin in cancer tissue and normal mammary gland tissue, evaluated  using real-time RT-PCR Relative expression level of lysophosphatidic acid receptors' mRNA against β-actin in cancer tissue and normal mammary gland tissue, evaluated 
using real-time RT-PCR: (a) Lysophosphatidic acid receptor 1 (LPA1), (b) LPA2 and (c) LPA3. Y axis indicates the cDNA copies for lysophospha-
tidic acid receptors divided by that of β-actin in each case. *P < 0.05.
Figure 3
Staining patterns of lysophosphatidic acid receptor 2 (LPA2) in normal  mammary epithelium (upper left) and carcinoma tissues (upper right) of  a representative case with high expression, and in another tumour tis- sue sample with low expression of LPA2 (lower left) Staining patterns of lysophosphatidic acid receptor 2 (LPA2) in normal 
mammary epithelium (upper left) and carcinoma tissues (upper right) of 
a representative case with high expression, and in another tumour tis-
sue sample with low expression of LPA2 (lower left). Some of the nor-
mal epithelial cells in the same specimens, as well as interstitial cells, 
are slightly stained, but the intensity is significantly weaker than that in 
carcinoma cells with high expression of LPA2. LPA2 can be detected in 
the cytoplasm as well as in the cell membrane, but not in the nucleus 
(lower right).Available online http://breast-cancer-research.com/content/6/6/R640
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pathological findings in these 84 cases are presented in
Table 2. High expression of LPA2 was frequently detected
in relatively old postmenopausal patients. High expression
of LPA2 was detected in 17 out of 38 (45%) premenopau-
sal patients and in 31 out of 46 (67%) postmenopausal
women; this difference was statistically significant (P  <
0.05). LPA2 expression did not correlate with oestrogen
receptor expression. The frequency of nodal or distant
metastasis tended to be higher in tumours with low expres-
sion of LPA2, although the difference was not statistically
significant.
Discussion
In the present study we found that breast cancer frequently
exhibited enhanced expression of LPA2 mRNA as com-
pared with normal breast gland tissue, although the expres-
sion level of LPA1 and that of LPA3 were not significantly
different from those in normal tissue. Over-expression of
LPA2 was confirmed at the protein level in some of these
cases by immunohistochemical staining. Previous studies
showed that LPA1 is widely expressed in various tissues,
whereas LPA2 and LPA3 are known to be highly expressed
in malignant cells, suggesting the potential role of these
receptors in the pathophysiology of cancer
[5,18,19,21,22]. Our findings regarding LPA2 are basically
consistent with those results and suggest that upregulation
of the LPA2 gene is a common feature of carcinogenesis in
various organs.
Protein expression of LPA2 in various organs has not been
investigated thus far because of the lack of an appropriate
antibody against LPA2. Our antibody clearly detected sig-
nificantly enhanced expression of LPA2 in more than half of
the ductal carcinoma cells, and the staining pattern exhib-
ited a strong correlation with the mRNA data obtained with
quantitative RT-PCR. Normal epithelium of mammary
Table 2
The relationship between lysophosphatidic acid receptor 2 (LPA2) expression and clinical/pathological factor
LPA2 expression Low (36) High (48) P
Age (years)
<50 20 (56%) 16 (33%) 0.042
≥50 16 (44%) 32 (67%)
Tumour size
T1 (≤2.0 cm) 16 (44%) 17 (35%) NS
T2 (>2.0 cm to ≤5.0 cm) 18 (50%) 25 (52%)
T3 (>5.0 cm) 2 (6%) 6 (13%)
Nuclear grade
I 5 (14%) 5 (10%) NS
II 24 (67%) 31 (65%)
III 7 (19%) 12 (25%)
Menopausal status
Premenopausal 21 (58%) 17 (35%) 0.037
Postmenopausal 15 (42%) 31 (65%)
Oestrogen receptor status
Negative 10 (55%) 27 (56%) NS
Positive 8 (45%) 21 (44%)
Nodal metastasis
Negative 12 (33%) 21 (44%) NS
Positive 24 (67%) 27 (56%)
Distant metastasis
Negative 27 (75%) 41 (85%) NS
Positive 9 (25%) 7 (15%)
Numbers in parentheses indicate percentages in the same expression pattern. NS, not significant.Breast Cancer Research    Vol 6 No 6    Kitayama et al.
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glands also showed slight immunoreactivity, but the stain-
ing intensity was markedly weaker than that of carcinoma
cells in these cases. Positive staining was mostly detected
in the cytosol and cellular membrane of carcinoma cells,
although the distribution of immunoreactivity differed
among the cells in each case, indicating that the cellular
distribution of LPA2 is highly heterogeneous, even within
the same tumour.
The exact role played over-expression of LPA2 in breast
carcinogenesis is not yet clear. However, in ovarian cancer
cells the proliferative responses to LPA of ovarian cancer
cells with high levels of LPA1 receptor were uniformly
weaker than those of cells with low LPA1 receptor levels
[22]. Moreover, LPA1 has been reported to transduce the
inhibitory signal to LPA2-mediated proliferative responses
and concurrently elicits apoptosis and anoikis [23]. On the
other hand, LPA has been shown to have an antiapoptotic
effect on various cells, although the LPA receptor that
mediates this response has not been determined [24,25].
Deng and coworkers [26] reported that LPA prevents
apoptosis of rat intestinal epithelial cells (IEC-6) induced by
radiation and chemotherapeutic agents. In that study they
used receptor specific inhibitors and concluded that the
antiapoptotic effect was mediated through both LPA1 and
LPA2. Thus, LPA1 can mediate both antiapoptotic and
apoptotic effects, and this is apparently dependent on the
cell type and circumstances. Taken together, these findings
indicate that the stimulation of LPA1 receptor has suppres-
sive effects, at least in part, on cell proliferation as com-
pared with the LPA2 receptor. Thus, the enhanced
expression of LPA2 with relatively reduced expression of
LPA1 appears to promote mammary epithelial cell survival
in LPA-rich circumstances and to favour development of
breast cancer.
Immunohistochemical finding showed that LPA2 is upreg-
ulated more frequently in postmenopausal than in premen-
opausal women, suggesting that over-expression of LPA2
is more strongly related to the carcinogenesis of postmen-
opausal breast cancer. It is well known that a high-fat diet
has a positive association with development of breast can-
cer, especially postmenopausal breast cancer, although
some conflicting findings have also been reported [27-32].
A high-fat diet is often associated with the insulin resist-
ance syndrome, and hyperinsulinaemia and high level of
insulin-like growth factor (IGF) have also been reported to
be markers of increased breast cancer risk [33-36].
Recently, receptors for IGF-1 were shown to be function-
ally expressed in mammary epithelium [37-39]. Moreover,
the IGF-mediated intracellular signal closely interacts with
the LPA-mediated signal, although the specific mechanism
is not yet known [40-43]. Therefore, our data raise the pos-
sibility that a shift in LPA receptor expression may alter the
effects of the LPA on IGF-mediated signal in mammary epi-
thelial cells, which may be closely associated with adipos-
ity-related carcinogenesis of breast cancer. The crosstalk
between the LPA1- or LPA2-mediated signal and the IGF-
or insulin-mediated signal remains an interesting subject for
future study.
In summary, we found preferential expression of LPA2 in
ductal carcinoma as compared with normal epithelium in
human mammary gland tissue. Over-expression of LPA2
was more prominent in postmenopausal women. A shift in
LPA receptor expression in mammary epethelium may be a
key event, especially in adiposity-related breast carcino-
genesis. LPA and its receptors could represent new chem-
opreventive targets in a novel therapeutic strategy in human
breast cancer.
Conclusion
Human ductal carcinoma cells frequently exhibited
enhanced expression of LPA2 as compared with normal
epithelium in human mammary gland tissue, especially in
postmenopausal women. This suggests that upregulation
of LPA2 may be one of the key events in carcinogenesis,
especially in adiposity-related breast cancer.
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